Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026
Rhea-AI Summary
Madrigal Pharmaceuticals (NASDAQ:MDGL) will participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 on June 10, 2026, at 11:20 A.M. EDT.
The presentation will be available via live webcast through Madrigal’s Investor Relations Events and Presentations page, with a replay offered after the event.
Positive
- None.
Negative
- None.
News Market Reaction – MDGL
In the Jun 3 session, MDGL gained 7.79%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.0% during that session. Our momentum scanner triggered 47 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 27 | Clinical outcomes data | Positive | +0.7% | Phase 3 and real-world Rezdiffra data on cardiovascular and liver risk markers. |
| May 21 | Inducement equity grants | Neutral | +0.7% | Equity inducement RSU awards to 15 non-executive employees under 2025 plan. |
| May 20 | Conference data preview | Positive | -1.3% | Planned EASL 2026 presentations on Rezdiffra cardiovascular and portal hypertension markers. |
| May 07 | Inducement equity awards | Negative | -4.6% | Stock options and RSUs granted to 47 new employees with vesting over four years. |
| May 06 | Earnings and pipeline | Positive | +7.4% | Q1 2026 results with strong Rezdiffra net sales, cash position, and pipeline expansion. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has generally been positive, with the stock often reacting in the same direction as the news tone, but occasionally selling off on favorable clinical or conference-related updates.
Over the last month, Madrigal has highlighted strong commercialization of Rezdiffra and expanding clinical data. On May 6, Q1 2026 results showed robust revenue growth and a higher net loss, with shares rising 7.42%. Subsequent inducement grant announcements on May 7 and May 21 coincided with mixed reactions, including a 4.64% decline. New MASH data and upcoming EASL 2026 presentations around May 20–27 produced modest moves. Against this backdrop, today’s conference-participation news is relatively routine.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CONSHOHOCKEN, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 on Wednesday, June 10, 2026, at 11:20 A.M. EDT.
The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page. A replay of the webcast will be available after the event.
About Madrigal
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com and follow us on LinkedIn.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
